Oncolytics Biotech (ONCY) adds information circular to Form F-10

Rhea-AI Filing Summary

Oncolytics Biotech Inc. filed a Form 6-K as a foreign private issuer. The filing mainly updates how certain shareholder information is incorporated into an existing Canadian shelf-style registration statement on Form F-10. It states that Exhibit 99.1 to this Form 6-K, an information circular previously filed on July 8, 2025, is now incorporated by reference into Oncolytics Biotech Inc.’s Form F-10 registration statement (File No. 333-281009). The report is signed on behalf of the company by its Chief Financial Officer, Kirk Look.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

For the month of August 2025

Commission File Number 000-38512

Oncolytics Biotech Inc.

(Translation of registrant’s name into English)

Suite 804, 322 11th Avenue SW

Calgary, Alberta, Canada T2R 0C5

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F   x Form 40-F   ¨

INCORPORATION BY REFERENCE

Exhibit 99.1 set forth below on this Form 6-K is hereby incorporated by reference as an exhibit to the Registration Statement on Form F-10 of Oncolytics Biotech Inc. (File No. 333-281009), as amended or supplemented.

DOCUMENTS FILED

EXHIBIT NUMBER		DESCRIPTION
99.1		Information Circular, incorporated by reference to Exhibit 99.1 to the registrant’s Foreign Issuer Report on Form 6-K as filed with the Commission on July 8, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Oncolytics Biotech Inc. (Registrant)
Date:  August 8, 2025	By:	/s/  Kirk Look
		Kirk Look
		Chief Financial Officer

FAQ

What did Oncolytics Biotech Inc. (ONCY) file in this Form 6-K?

Oncolytics Biotech Inc. filed a Form 6-K that incorporates an information circular, identified as Exhibit 99.1, into its existing Form F-10 registration statement.

How is the information circular used in Oncolytics Biotech Inc. (ONCY)'s U.S. registration?

The information circular in Exhibit 99.1 is incorporated by reference as an exhibit to Oncolytics Biotech Inc.’s Form F-10 registration statement, File No. 333-281009.

Which exhibit is referenced in this Oncolytics Biotech Inc. (ONCY) Form 6-K?

The Form 6-K references Exhibit 99.1, described as an information circular that was previously filed as Exhibit 99.1 to another Form 6-K on July 8, 2025.

Who signed this Oncolytics Biotech Inc. (ONCY) Form 6-K?

The report was signed on behalf of Oncolytics Biotech Inc. by its Chief Financial Officer, Kirk Look.

Where is Oncolytics Biotech Inc. (ONCY) headquartered according to this filing?

Oncolytics Biotech Inc. lists its principal executive offices at Suite 804, 322 11th Avenue, Calgary, Alberta, Canada T2R 0C5.